Antithymocyte immunoglobulin (equine) 100mg/5ml solution for infusion vials
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 30 studies.
Reviews & meta-analyses: 3 · Randomised trials: 1 · 1971–2020
Showing all 30 studies, sorted by most relevant.
J. Finke, C. Schmoor, W. Bethge, et al.
The Lancet. Haematology, 2017
- Graft vs Host Disease
- Immunoglobulins
- Methotrexate
F. Sánchez‐Madrid, A. Krensky, C. Ware, et al.
Proceedings of the National Academy of Sciences of the United States of America, 1982
- Antibodies, Monoclonal
- Histocompatibility Antigens Class II
- Antigens, Surface
ROGER B. TAYLOR, W. PHILIP H. DUFFUS, MARTIN C. RAFF, et al.
Nature New Biology, 1971
- Pinocytosis
- Antibodies
- Antigens
JP Van Wauwe, JR DeMay, JG Goossens
Journal of immunology, 1980
- Antibodies
- B-Lymphocytes
- Binding Sites, Antibody
N. Weng, Bruce L. Levine, Carl H. June, et al.
The Journal of Experimental Medicine, 1996
- Lymphocyte Activation
- Flow Cytometry
- T-Lymphocytes
D. Taub, S. Turcovski-Corrales, M. Key, et al.
Journal of immunology, 1996
- Antibodies, Monoclonal
- Calcium
- Clone Cells
F. Piller, V. Piller, R. Fox, et al.
The Journal of biological chemistry, 1988
- Lymphocyte Activation
- Antigens, CD
- Carbohydrate Conformation
The activation of human T-lymphocytes by anti-CD3 antibodies and interleukin-2 results in a marked increase in apparent molecular weight of the major cell-surface sialoglycoprotein. Both forms of the sialoglycoprotein were identified as leukosialin by a monospecific antiserum, and the differences in molecular weight were found to be due to changes in the carbohydrate structures. Our results suggest that resting T-lymphocytes express on leukosialin the disialotetrasaccharides NeuNAc alpha 2----3Gal beta 1----3(NeuNAc alpha 2----6)Gal-NAc-Ser/Thr, whereas activated human T-cells carry on leukosialin exclusively the more complex structures NeuNAc alpha 2----3Gal beta 1----3(NeuNAc alpha 2----3Gal beta 1----4GlcNAc beta 1----6)GalNAc-Ser/Thr. The radical shift in the biosynthetic pathway of O-glycans in activated T-lymphocytes compared to resting cells is apparently caused by a decrease of alpha 2----6 sialyltransferase activity and by the parallel dramatic stimulation of the beta 1----6GlcNAc-transferase. Since both enzymes compete for the same precursor substrate, the coordinate changes in their activities are most likely responsible for the complete change of the carbohydrate structures on leukosialin during the activation of human T-lymphocytes.
Abstract licence: CC BY
Shi‐Hua Lin, R. Boltz, J. T. Blake, et al.
The Journal of Experimental Medicine, 1993
- Calcium
- Cell Division
- Cells, Cultured
S. Yokota, T. Geppert, P. Lipsky
Journal of immunology, 1988
- Antibodies, Monoclonal
- Antigens, Bacterial
- Antigens, Differentiation, T-Lymphocyte
N E Phillips, D C Parker
The Journal of Immunology, 1984
- Lymphocyte Activation
- Antibodies, Anti-Idiotypic
- Antibodies, Monoclonal
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.